Fresenius in license agreement with Sanofi-Aventis

Fresenius Kabi Oncology Ltd has entered into a license and settlement agreement with Sanofi-Aventis for injectable drug Eloxatin. The agreement resolves a patent infringement suit filed by Sanofi-Aventis in June 2007 in the US. Eloxatin is used for the treatment of stage-III colon cancer. The drug had net sales of $993 million in the US market in year 2009.